Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis

Clin Lung Cancer. 2019 Sep;20(5):e552-e554. doi: 10.1016/j.cllc.2019.06.002. Epub 2019 Jun 13.

Authors

Dipesh Uprety¹, Lubina Arjyal², Yazhini Vallatharasu², Amir Bista², Richard J Wittchow², David E Marinier²

Affiliations

¹ Gundersen Health System, La Crosse, WI. Electronic address: upretydipesh@gmail.com.
² Gundersen Health System, La Crosse, WI.

PMID: 31285178
DOI: 10.1016/j.cllc.2019.06.002

No abstract available

Keywords: Durable response; Immunotherapy; NSCLC; Pembrolizumab; Stage IV.

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Biomarkers, Pharmacological
Brain Neoplasms / drug therapy*
Brain Neoplasms / secondary
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / secondary
Female
Humans
Immunotherapy / methods*
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Neoplasm Staging
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Biomarkers, Pharmacological
pembrolizumab